Nuclear Receptor 4A1 (NR4A1) and NR4A2 Regulate Expression of O6-Methylguanine-DNA-Methyltransferase (MGMT) in Glioblastoma and Can Be Targeted by NR4A1/2 Ligands

Purpose Glioblastoma (GBM) is highly malignant and aggressive with limited treatment options. Resistance to the standard of care temozolomide (TMZ) is associated with expression of O 6 -methylguanine-DNA-methyltransferase (MGMT). This study investigates whether orphan nuclear receptor 4A1 (NR4A1) and NR4A2 regulate MGMT expression in GBM cells and whether DIM-3,5 compounds decrease MGMT expression and could be used to enhance TMZ efficacy in GBM cells. Methods Human and mouse GBM cell lines were used. Cells were treated with DIM-3,5 compounds and TMZ to evaluate cell proliferation. RNA interference was used to knockdown NR4A1/2, Sp1, or MGMT. MGMT mRNA and protein expression was measured using qrt-PCR and Western blotting. Luciferase reporter assays examined MGMT promoter activity, while chromatin immunoprecipitation (ChIP) assays investigated transcription factor interactions on the MGMT promoter. Results DIM-3,5 compounds significantly decreased GBM cell proliferation in all cell lines. DIM-3,5 compounds or knockdown of NR4A1/2 or Sp1 significantly decreased MGMT mRNA, protein, and luciferase promoter expression in all cell lines. ChIP analysis demonstrated that NR4A1 and NR4A2 regulate MGMT through interactions with a NBRE motif and Sp1 regulates MGMT through GC-rich promoter regions. Additionally, MGMT knockdown increased TMZ-induced cytotoxicity in GBM cells. Conclusion This study shows that NR4A1/2/Sp1 are involved in MGMT regulation through complex mechanisms that include regulation by Sp1 alone and by direct interaction of NR4A1 and NR4A2 as monomers with an NBRE motif. DIM-3,5 ligands act as inverse NR4A1/2 agonists and downregulate MGMT expression in GBM cells.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11627997/v1
Primary Topic
Glioma Diagnosis and Treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Nuclear Receptor 4A1 (NR4A1) and NR4A2 Regulate Expression of O6-Methylguanine-DNA-Methyltransferase (MGMT) in Glioblastoma and Can Be Targeted by NR4A1/2 Ligands

Srijana Upadhyay, Wai Ning Tiffany Tsui, Karol Bomsztyk, Daniel Mar et al.
3 links
Research Square
Glioma Diagnosis and Treatment
preprint

Nuclear Receptor 4A1 (NR4A1) and NR4A2 Regulate Expression of O6-Methylguanine-DNA-Methyltransferase (MGMT) in Glioblastoma and Can Be Targeted by NR4A1/2 Ligands

Srijana Upadhyay, Wai Ning Tiffany Tsui, Karol Bomsztyk, Daniel Mar, Arafat Rahman Oany, Gargi Sivaram, Svetlana A. Mikheeva, Evan Farkas, Stephen Safe, Ana Gutierrez, Andrei Mikheev, Robert Rostomily, Sofia Melgoza
preprint en

Abstract

Purpose Glioblastoma (GBM) is highly malignant and aggressive with limited treatment options. Resistance to the standard of care temozolomide (TMZ) is associated with expression of O 6 -methylguanine-DNA-methyltransferase (MGMT). This study investigates whether orphan nuclear receptor 4A1 (NR4A1) and NR4A2 regulate MGMT expression in GBM cells and whether DIM-3,5 compounds decrease MGMT expression and could be used to enhance TMZ efficacy in GBM cells. Methods Human and mouse GBM cell lines were used. Cells were treated with DIM-3,5 compounds and TMZ to evaluate cell proliferation. RNA interference was used to knockdown NR4A1/2, Sp1, or MGMT. MGMT mRNA and protein expression was measured using qrt-PCR and Western blotting. Luciferase reporter assays examined MGMT promoter activity, while chromatin immunoprecipitation (ChIP) assays investigated transcription factor interactions on the MGMT promoter. Results DIM-3,5 compounds significantly decreased GBM cell proliferation in all cell lines. DIM-3,5 compounds or knockdown of NR4A1/2 or Sp1 significantly decreased MGMT mRNA, protein, and luciferase promoter expression in all cell lines. ChIP analysis demonstrated that NR4A1 and NR4A2 regulate MGMT through interactions with a NBRE motif and Sp1 regulates MGMT through GC-rich promoter regions. Additionally, MGMT knockdown increased TMZ-induced cytotoxicity in GBM cells. Conclusion This study shows that NR4A1/2/Sp1 are involved in MGMT regulation through complex mechanisms that include regulation by Sp1 alone and by direct interaction of NR4A1 and NR4A2 as monomers with an NBRE motif. DIM-3,5 ligands act as inverse NR4A1/2 agonists and downregulate MGMT expression in GBM cells.

Research Square
Houston Methodist (US), University of Washington (US), Houston Methodist Research Institute (US), Texas A&M University (US)
National Institutes of Health
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon